XML 40 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Summary Of Significant Accounting Policies - Narrative (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
feet
Jun. 30, 2019
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2016
USD ($)
New Accounting Pronouncement, Early Adoption [Line Items]                  
Restricted cash $ 100,000   $ 100,000       $ 100,000    
Revenue 8,948,000 $ 10,474,000 18,532,000 $ 19,734,000          
Advertising Expense 300,000 400,000 $ 700,000 700,000          
Number of operating segments | feet     1            
Janssen (SIMPONI®)                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Revenue 2,100,000 300,000 $ 2,100,000 400,000          
Forecast                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Joint venture quarterly promotion fee cap         5.00% 5.00%      
Minimum                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Joint venture, quarterly promotion fee per prescription               $ 750  
Minimum | Forecast                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Joint venture, quarterly promotion fee         $ 300,000 $ 300,000      
Maximum                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Joint venture, quarterly promotion fee per prescription               $ 1,250  
Other assets                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Restricted cash                 $ 100,000
Shipping and Handling                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Cost of revenue $ 300,000 $ 400,000 $ 700,000 $ 700,000          
Revenue Benchmark | Product Concentration Risk | AVISE CTD Test                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Percent of total revenue 60.00% 82.00% 72.00% 83.00%          
Revenue Benchmark | Supplier Concentration Risk | Two Suppliers                  
New Accounting Pronouncement, Early Adoption [Line Items]                  
Percent of total revenue 97.00% 97.00% 97.00% 96.00%